Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab.


A still relevant number of patients with RAS-BRAF wild-type colorectal cancer (CRC) do not respond to treatment with antiepidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab and panitumumab, suggesting that additional biomarkers to guide patient selection are urgently needed. Circulating tumor cells (CTCs) may represent such a biomarker… (More)
DOI: 10.1002/ijc.29493


6 Figures and Tables


Citations per Year

Citation Velocity: 14

Averaging 14 citations per year over the last 3 years.

Learn more about how we calculate this metric in our FAQ.